The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Discovery of a novel shared tumor antigen in human lung cancer.
 
Diane Tseng
Stock and Other Ownership Interests - Forty Seven
Honoraria - Apple (I)
Patents, Royalties, Other Intellectual Property - Forty Seven
 
Shin-Heng Chiou
No Relationships to Disclose
 
Xinbo Yang
No Relationships to Disclose
 
Alexandre Reuben
No Relationships to Disclose
 
Julie Wilhelmy
No Relationships to Disclose
 
Alana McSween
No Relationships to Disclose
 
Stephanie Conley
No Relationships to Disclose
 
Rahul Sinha
Consulting or Advisory Role - Forty Seven; Stem Cells, Inc.
 
Barzin Nabet
Patents, Royalties, Other Intellectual Property - I have a patent pending related to immunomodulatory nucleic acids. (Inst)
 
Chunlin Wang
Employment - Chapter Diagnostics; iRepertoire
Leadership - Chapter Diagnostics
Stock and Other Ownership Interests - Chapter Diagnostics; iRepertoire
Consulting or Advisory Role - iRepertoire
Patents, Royalties, Other Intellectual Property - Immucor
Travel, Accommodations, Expenses - Chapter Diagnostics; iRepertoire
 
Joseph B Shrager
Consulting or Advisory Role - Becton Dickinson
Research Funding - Varian Medical Systems
Patents, Royalties, Other Intellectual Property - a potential pharmacological means of preventing ventilator-induced diaphragm dysfunction -a potential use of CRISPR for EGFR mutant lung cancer therapy
 
Mark F. Berry
No Relationships to Disclose
 
Leah Monique Backhus
Employment - Department of Veteran Affairs; Stanford University
Leadership - ACGME; Patient-Centered Outcomes Research Institute (PCORI)
Other Relationship - Patient-Centered Outcomes Research Institute (PCORI)
 
Natalie Lui
Research Funding - Auspex Pharmaceuticals
Travel, Accommodations, Expenses - Intuitive Surgical
 
Heather A. Wakelee
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Helsinn Therapeutics; Janssen Oncology; Mirati Therapeutics; Xcovery
Research Funding - ACEA Biosciences (Inst); Arrys Therapeutics (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Exelixis (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Merck (Inst); Novartis (Inst); Pharmacyclics (Inst); Xcovery (Inst)
Travel, Accommodations, Expenses - AstraZeneca
(OPTIONAL) Uncompensated Relationships - Genentech/Roche; Merck; Takeda
 
Joel W. Neal
Honoraria - Biomedical Learning Institute; CME Matters; Medscape; MJH Life Sciences; MLI Peerview; Prime Oncology; Research to Practice; Rockpointe
Consulting or Advisory Role - AstraZeneca; Calithera Biosciences; Exelixis; Genentech/Roche; Jounce Therapeutics; Lilly; Takeda
Research Funding - Adaptimmune (Inst); Boehringer Ingelheim (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Up To Date - Royalties
 
Jianjun Zhang
Honoraria - CancerNet; Geneplus; Geneplus; Innovent Biologics; innovent biologics; Origimed; Roche; Sino-USA Biomedical Platform; Zhejiang Cancer Hospital; Zhejiang Cancer Hospital
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Capital Medical University; Geneplus
Research Funding - Merck
Travel, Accommodations, Expenses - innovent biologics; Zhejiang Cancer Hospital
 
K. Christopher Garcia
Stock and Other Ownership Interests - 3T BioSciences; ALX Oncology; Surrozen; Synthekine
Honoraria - Genentech; Merck
Consulting or Advisory Role - ALX Oncology; Dragonfly Therapeutics; NGM Biopharmaceuticals; Surrozen; Synthekine
Patents, Royalties, Other Intellectual Property - 3T BioSciences; ALX Oncology; Surrozen; Synthekine
Expert Testimony - Biogen; Kite, a Gilead company
 
Crystal Mackall
Stock and Other Ownership Interests - Alimera Sciences; Apricity Health; Lyell Immunopharma; Vor Biopharma
Consulting or Advisory Role - Alimera Sciences; Apricity Health; Bryology; Lyell Immunopharma; Nektar; NeoImmuneTech; PACT Pharma; TPG; Vor Biopharma
Patents, Royalties, Other Intellectual Property - I am an inventor on numerous patents related to chimeric antigen receptor therapeutics and received royalties from NIH for the CD22-CAR patent licensed to Juno therapeutics.
Travel, Accommodations, Expenses - Nektar; NeoImmuneTech; Roche
Other Relationship - Lyell Immunopharma
 
Mark Davis
Stock and Other Ownership Interests - 3T Bio, Inc; A2 Biotherapeutics; Abbvie; Accendio Pharma; Adicet Bio; Amgen; Atreca; Bridge Bio Pharma; Bristol Myers Squibb Foundation; Celldex; Chugai Pharma; Concert Pharmaceuticals; Eidos Therapeutics; Exelitis, Inc.; Gilead Sciences; IgM Biosciences; Janux; Medikine; MEI Pharma; Moderna Therapeutics; Pact Bio; Quadriga; Verona Pharma; VIR Biotechnology
Honoraria - 3T Bio, Inc; A2 Biotherapeutics; Adicent; Amgen; Chugai Pharma; IgM Biosciences; Janux; Pact Bio; VIR Biotechnology
Consulting or Advisory Role - 3T Bio, Inc; A2 Biotherapeutics; Adicent; Amgen; Chugai Pharma; IgM Biosciences; Janux; Medikine; Pact Bio; Quadriga; VIR Biotechnology
Patents, Royalties, Other Intellectual Property - A candidate antigen for the initiation and treatment of Multiple Sclerosis; A inflammatory signature to detect the cancer up to 3 years prior to clinical diagonisis; A method to identify immunodeficient subjects at risk for chronic disease; A novel class of T lymphocytes in autoimmune diseases that may trigger disease supression; Injectable hydrogels for controlled release of immunomodulatory compounds; Lymphocyte specificity in neurological disease; Method of predicting hepatitis C viral relapse following direct-acting antiviral treatment with pre-treatment level of circulating brain-derived neurotrophic factor; Mutated NPM1 as a neoantigen target for cancer immunotherapy; Simultaneous measurement of RNA sequence and accessible chromatin sites in single- and ensemble cells; Toll-like receptor agonist containing nanoparticles for enhancingimmune checkpoint blockade efficacy